Editas Drugs, Inc. (NASDAQ:EDIT – Get Ranking) gapped up earlier than the market opened on Tuesday . The inventory had beforehand closed at $17.12, however opened at $18.78. Editas Drugs shares final traded at $17.03, with a quantity of 65,785 shares.
A number of analysis companies have lately issued studies on EDIT. Morgan Stanley lowered their value goal on Editas Drugs from $37.00 to $24.00 and set an “underweight” ranking for the corporate in a analysis report on Thursday, January sixth. Oppenheimer lowered their value goal on Editas Drugs from $80.00 to $55.00 and set an “outperform” ranking for the corporate in a analysis report on Friday, February twenty fifth. SVB Leerink lowered their value goal on Editas Drugs from $41.00 to $27.00 and set a “market carry out” ranking for the corporate in a analysis report on Friday, February twenty fifth. Barclays lowered their goal value on shares of Editas Drugs from $39.00 to $18.00 in a report on Friday, February twenty fifth. Lastly, Zacks Funding Analysis upgraded shares of Editas Drugs from a “maintain” ranking to a “purchase” ranking and set a $20.00 goal value for the corporate in a report on Thursday, February third. Two equities analysis analysts have rated the inventory with a promote ranking, 5 have given a maintain ranking and 6 have issued a purchase ranking to the corporate. In accordance with knowledge from MarketBeat, Editas Drugs at the moment has a consensus ranking of “Maintain” and a mean value goal of $38.58.
The enterprise has a fifty day easy shifting common of $20.48 and a 200 day easy shifting common of $36.22. The corporate has a market cap of $1.17 billion, a price-to-earnings ratio of -6.02 and a beta of 1.96.
Editas Drugs (NASDAQ:EDIT – Get Ranking) final posted its quarterly earnings outcomes on Thursday, February twenty fourth. The corporate reported ($0.61) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.28. Editas Drugs had a unfavorable internet margin of 753.61% and a unfavorable return on fairness of 32.19%. The corporate had income of $12.50 million in the course of the quarter, in comparison with the consensus estimate of $4.70 million. Throughout the identical interval final 12 months, the agency earned ($1.00) EPS. The corporate’s income for the quarter was up 9.6% on a year-over-year foundation. Analysis analysts forecast that Editas Drugs, Inc. will publish -3.23 EPS for the present fiscal 12 months.
In different information, CFO Michelle Robertson offered 1,744 shares of Editas Drugs inventory in a transaction on Tuesday, January eleventh. The inventory was offered at a mean value of $25.70, for a complete transaction of $44,820.80. The transaction was disclosed in a submitting with the Securities & Alternate Fee, which is accessible by the SEC web site. Insiders personal 0.44% of the corporate’s inventory.
Institutional buyers and hedge funds have lately modified their holdings of the enterprise. State Avenue Corp elevated its stake in shares of Editas Drugs by 51.7% in the course of the 4th quarter. State Avenue Corp now owns 3,274,607 shares of the corporate’s inventory valued at $86,941,000 after buying an extra 1,116,589 shares over the past quarter. Victory Capital Administration Inc. elevated its stake in shares of Editas Drugs by 2,523.4% in the course of the third quarter. Victory Capital Administration Inc. now owns 1,118,909 shares of the corporate’s inventory valued at $45,964,000 after buying an extra 1,076,258 shares over the past quarter. Millennium Administration LLC elevated its stake in shares of Editas Drugs by 2,783.7% in the course of the 4th quarter. Millennium Administration LLC now owns 988,290 shares of the corporate’s inventory valued at $26,239,000 after buying an extra 1,025,116 shares over the past quarter. Lord Abbett & CO. LLC acquired a brand new place in shares of Editas Drugs in the course of the third quarter valued at about $29,059,000. Lastly, Marshall Wace LLP acquired a brand new stake in shares of Editas Drugs in the course of the 4th quarter price $10,264,000. Institutional buyers personal 67.71% of the corporate’s inventory.
Editas Drugs Firm Profile (NASDAQ:EDIT)
Editas Drugs, Inc engages within the growth and commercialization of genome modifying know-how. Its know-how consists of clustered, recurrently interspaced quick palindromic repeats (CRISPR), and CRISPR related protein 9 (Cas9). The corporate was based by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.
Need Extra Nice Investing Concepts?
Obtain Information & Scores for Editas Drugs Day by day – Enter your e mail tackle beneath to obtain a concise each day abstract of the newest information and analysts’ rankings for Editas Drugs and associated firms with MarketBeat.com’s FREE each day e mail e-newsletter.